Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature
Abstract
:1. Introduction
2. Methods
3. Results
3.1. Non-Clinical Data
3.2. Oxidative Stress, Cardiac Fibrosis, and Remodeling
3.3. Electrical Remodeling
4. Clinical Data
4.1. Oxidative Stress, Fibrosis, Thrombosis, and Remodeling
4.2. Electrical Remodeling
4.3. Relation to Left Ventricular Ejection Fraction and Other Biomarkers
4.4. Adrenergic Effect
5. Discussion
6. Future Research
7. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Lippi, G.; Sanchis-Gomar, F.; Cervellin, G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke 2021, 16, 217–221. [Google Scholar] [CrossRef]
- Iwasaki, Y.-K.; Nishida, K.; Kato, T.; Nattel, S. Atrial fibrillation pathophysiology. Circulation 2011, 124, 2264–2274. [Google Scholar] [CrossRef] [PubMed]
- Korantzopoulos, P.; Letsas, K.P.; Tse, G.; Fragakis, N.; Goudis, C.A.; Liu, T. Inflammation and atrial fibrillation: A comprehensive review. J. Arrhythmia 2018, 34, 394–401. [Google Scholar] [CrossRef] [PubMed]
- Neal, B.; MacMahon, S.; Ohkubo, T.; Tonkin, A.; Wilcken, D. Pacific study group dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur. Heart J. 2002, 23, 1509–1515. [Google Scholar] [CrossRef] [PubMed]
- Mehlig, K.; Leander, K.; De Faire, U.; Nyberg, F.; Berg, C.; Rosengren, A.; Björck, L.; Zetterberg, H.; Blennow, K.; Tognon, G.; et al. The association between plasma homocysteine and coronary heart disease is modified by the MTHFR 677C>T polymorphism. Heart 2013, 99, 1761–1765. [Google Scholar] [CrossRef]
- Cattaneo, M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost. 1999, 81, 165–176. [Google Scholar] [CrossRef]
- Martí-Carvajal, A.J.; Solà, I.; Lathyris, D.; Salanti, G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst. Rev. 2009, CD006612. [Google Scholar] [CrossRef]
- Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Dilaveris, P.E.; et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021, 42, 373–498. [Google Scholar] [PubMed]
- Zoni-Berisso, M.; Lercari, F.; Carazza, T.; Domenicucci, S. Epidemiology of atrial fibrillation: European perspective. Clin. Epidemiol. 2014, 6, 213–220. [Google Scholar] [CrossRef]
- Friberg, L.; Hammar, N.; Pettersson, H.; Rosenqvist, M. Increased mortality in paroxysmal atrial fibrillation: Report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur. Heart J. 2007, 28, 2346–2353. [Google Scholar] [CrossRef]
- Kubota, Y.; Alonso, A.; Heckbert, S.R.; Norby, F.L.; Folsom, A.R. Homocysteine and incident atrial fibrillation: The atherosclerosis risk in communities study and the multi-ethnic study of atherosclerosis. Heart Lung Circ. 2019, 28, 615–622. [Google Scholar] [CrossRef] [PubMed]
- Marcucci, R.; Betti, I.; Cecchi, E.; Poli, D.; Giusti, B.; Fedi, S.; Lapini, I.; Abbate, R.; Gensini, G.F.; Prisco, D. Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation? Am. Heart J. 2004, 148, 456–461. [Google Scholar] [CrossRef] [PubMed]
- Nasso, G.; Bonifazi, R.; Romano, V.; Brigiani, M.S.; Fiore, F.; Bartolomucci, F.; Lamarra, M.; Fattouch, K.; Rosano, G.; Gaudino, M.; et al. Increased plasma homocysteine predicts arrhythmia recurrence after minimally invasive epicardial ablation for nonvalvular atrial fibrillation. J. Thorac. Cardiovasc. Surg. 2013, 146, 848–853. [Google Scholar] [CrossRef]
- Naji, F.; Suran, D.; Kanic, V.; Vokac, D.; Sabovic, M. High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion. Int. Heart J. 2010, 51, 30–33. [Google Scholar] [CrossRef] [PubMed]
- Shi, D.; Meng, Q.; Zhou, X.; Li, L.; Liu, K.; He, S.; Wang, S.; Chen, X. Factors influencing the relationship between atrial fibrillation and artery stiffness in elderly Chinese patients with hypertension. Aging Clin. Exp. Res. 2016, 28, 653–658. [Google Scholar] [CrossRef]
- Shimano, M.; Inden, Y.; Tsuji, Y.; Kamiya, H.; Uchikawa, T.; Shibata, R.; Murohara, T. Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace 2008, 10, 961–966. [Google Scholar] [CrossRef]
- Schnabel, R.B.; Larson, M.G.; Yamamoto, J.F.; Sullivan, L.M.; Pencina, M.J.; Meigs, J.B.; Tofler, G.H.; Selhub, J.; Jacques, P.F.; Wolf, P.A.; et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010, 121, 200–207. [Google Scholar] [CrossRef]
- Cingozbay, B.Y.; Yiginer, O.; Cebeci, B.S.; Kardesoglu, E.; Demiralp, E.; Dincturk, M. Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation. Blood Coagul. Fibrinolysis 2002, 13, 609–613. [Google Scholar] [CrossRef]
- Yao, Y.; Yao, W.; Bai, R.; Lu, Z.-H.; Tang, R.-B.; Long, D.-Y.; Jiang, C.-X.; Sang, C.-H.; Zhang, J.-Q.; Yu, R.-H.; et al. Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation. Europace 2017, 19, 66–71. [Google Scholar] [CrossRef]
- Yao, Y.; Shang, M.-S.; Dong, J.-Z.; Ma, C.-S. Homocysteine in non-valvular atrial fibrillation: Role and clinical implications. Clin. Chim. Acta 2017, 475, 85–90. [Google Scholar] [CrossRef]
- Giusti, B.; Gori, A.M.; Marcucci, R.; Sestini, I.; Saracini, C.; Sticchi, E.; Gensini, F.; Fatini, C.; Abbate, R.; Gensini, G.F. Role of C677T and A1298C MTHFR, A2756G MTR and -786 C/T eNOS gene polymorphisms in atrial fibrillation susceptibility. PLoS ONE 2007, 2, e495. [Google Scholar] [CrossRef] [PubMed]
- Svenningsson, M.M.; Svingen, G.F.; Lysne, V.; Ueland, P.M.; Tell, G.S.; Pedersen, E.R.; Dhar, I.; Nilsen, D.W.; Nygård, O. Transsulfuration metabolites and the association with incident atrial fibrillation—An observational cohort study among norwegian patients with stable angina pectoris. Int. J. Cardiol. 2020, 317, 75–80. [Google Scholar] [CrossRef] [PubMed]
- Rong, H.; Huang, L.; Jin, N.; Hong, J.; Hu, J.; Wang, S.; Xie, Y.; Pu, J. Elevated homocysteine levels associated with atrial fibrillation and recurrent atrial fibrillation. Int. Heart J. 2020, 61, 705–712. [Google Scholar] [CrossRef] [PubMed]
- Dong, X.; Wang, B.; Hou, F.; Chen, K.; Zhou, H.; Guo, J.; Sun, X.; Liu, X.; Chen, L. Homocysteine (HCY) levels in patients with atrial fibrillation (AF): A meta-analysis. Int. J. Clin. Pract. 2021, 75, e14738. [Google Scholar] [CrossRef] [PubMed]
- Bayrak, B.; Koroglu, P.; Bulan, O.K.; Yanardag, R. Metformin protects against diabetes-induced heart injury and dunning prostate cancer model. Hum. Exp. Toxicol. 2021, 40, 297–309. [Google Scholar] [CrossRef] [PubMed]
- Borkowska, A.; Ziolkowski, W.; Kaczor, K.; Herman-Antosiewicz, A.; Knap, N.; Wronska, A.; Antosiewicz, J. Homocysteine-induced decrease in HUVEC cells’ resistance to oxidative stress is mediated by Akt-dependent changes in iron metabolism. Eur. J. Nutr. 2020, 60, 1619–1631. [Google Scholar] [CrossRef]
- Cheng, C.K.; Luo, J.-Y.; Lau, C.W.; Cho, W.C.-S.; Ng, C.F.; Ma, R.C.W.; Tian, X.Y.; Huang, Y. A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction. Acta. Pharmacol. Sin. 2021, 42, 1598–1609. [Google Scholar] [CrossRef]
- Guo, J.; Qin, Z.; He, Q.; Fong, T.L.; Lau, N.C.; Cho, W.C.S.; Zhang, H.; Meng, P.; Xing, X.; Li, M.; et al. Shexiang baoxin pill for acute myocardial infarction: Clinical evidence and molecular mechanism of antioxidative stress. Oxid. Med. Cell. Longev. 2021, 2021, 7644648. [Google Scholar] [CrossRef]
- Sharma, G.S.; Bhattacharya, R.; Singh, L.R. Functional inhibition of redox regulated heme proteins: A novel mechanism towards oxidative stress induced by homocysteine. Redox Biol. 2021, 46, 102080. [Google Scholar] [CrossRef]
- Boyacioglu, M.; Sekkin, S.; Kum, C.; Korkmaz, D.; Kiral, F.; Yalinkilinc, H.S.; Ak, M.O.; Akar, F. The protective effects of vitamin C on the DNA damage, antioxidant defenses and aorta histopathology in chronic hyperhomocysteinemia induced rats. Exp. Toxicol. Pathol. 2014, 66, 407–413. [Google Scholar] [CrossRef]
- Aminzadeh, A.; Mehrzadi, S. Cardioprotective effect of levosimendan against homocysteine-induced mitochondrial stress and apoptotic cell death in H9C2. Biochem. Biophys. Res. Commun. 2018, 507, 395–399. [Google Scholar] [CrossRef] [PubMed]
- Derouiche, F.; Bôle-Feysot, C.; Naïmi, D.; Coëffier, M. Hyperhomocysteinemia-induced oxidative stress differentially alters proteasome composition and activities in heart and aorta. Biochem. Biophys. Res. Commun. 2014, 452, 740–745. [Google Scholar] [CrossRef] [PubMed]
- Aissa, A.F.; Amaral, C.L.D.; Venancio, V.P.; Machado, C.D.S.; Hernandes, L.C.; Santos, P.; Curi, R.; Bianchi, M.L.P.; Antunes, L.M.G. Methionine-supplemented diet affects the expression of cardiovascular disease-related genes and increases inflammatory cytokines in mice heart and liver. J. Toxicol. Environ. Health A 2017, 80, 1116–1128. [Google Scholar] [CrossRef] [PubMed]
- Dittoe, N.J.; Hahn, H.S.; Sansone, R.A.; Wiederman, M.W. Prevalence and self-reported medical history of overweight in a cardiac stress testing population. South Med. J. 2011, 104, 505–508. [Google Scholar] [CrossRef] [PubMed]
- Kolling, J.; Scherer, E.B.; da Cunha, A.A.; da Cunha, M.J.; Wyse, A.T. Homocysteine induces oxidative–nitrative stress in heart of rats: Prevention by folic acid. Cardiovasc. Toxicol. 2011, 11, 67–73. [Google Scholar] [CrossRef] [PubMed]
- Devi, S.; Kennedy, R.H.; Joseph, L.; Shekhawat, N.S.; Melchert, R.B.; Joseph, J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc. Pathol. 2006, 15, 75–82. [Google Scholar] [CrossRef]
- Han, L.; Wu, G.; Feng, C.; Yang, Y.; Li, B.; Ge, Y.; Jiang, Y.; Shi, Y.-H.; Le, G. Dietary methionine restriction improves the impairment of cardiac function in middle-aged obese mice. Food Funct. 2020, 11, 1764–1778. [Google Scholar] [CrossRef]
- Mendes, R.H.; Sirvente, R.A.; Candido, G.O.; Mostarda, C.T.; Salemi, V.; D’Almeida, V.; Jacob, M.H.; Ribeiro, M.F.; Belló-Klein, A.; Rigatto, K.; et al. Homocysteine thiolactone induces cardiac dysfunction: Role of oxidative stress. J. Cardiovasc. Pharmacol. 2010, 55, 198–202. [Google Scholar] [CrossRef]
- Singh, A.P.; Singh, M.; Balakumar, P. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J. Cardiovasc. Pharmacol. 2008, 51, 596–604. [Google Scholar] [CrossRef]
- Stojanovic, M.; Zivkovic, V.; Srejovic, I.; Jakovljevic, V.; Jeremic, N.; Djuric, D. The role of hydrogen sulfide in homocysteine-induced cardiodynamic effects and oxidative stress markers in the isolated rat heart. Physiol. Int. 2016, 103, 428–438. [Google Scholar] [CrossRef] [Green Version]
- Timkova, V.; Tatarkova, Z.; Lehotsky, J.; Racay, P.; Dobrota, D.; Kaplan, P. Effects of mild hyperhomocysteinemia on electron transport chain complexes, oxidative stress, and protein expression in rat cardiac mitochondria. Mol. Cell. Biochem. 2016, 411, 261–270. [Google Scholar] [CrossRef] [PubMed]
- Yalçinkaya-Demirsöz, S.; Depboylu, B.; Dogru-Abbasoglu, S.; Unlüçerçi, Y.; Uysal, M. Effects of high methionine diet on oxidative stress in serum, apo-B containing lipoproteins, heart, and aorta in rabbits. Ann. Clin. Lab. Sci. 2009, 39, 386–391. [Google Scholar] [PubMed]
- Chang, L.; Zhao, J.; Xu, J.; Jiang, W.; Tang, C.S.; Qi, Y.F. Effects of taurine and homocysteine on calcium homeostasis and hydrogen peroxide and superoxide anions in rat myocardial mitochondria. Clin. Exp. Pharmacol. Physiol. 2004, 31, 237–243. [Google Scholar] [CrossRef] [PubMed]
- Chang, L.; Xu, J.; Yu, F.; Zhao, J.; Tang, X.; Tang, C. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004, 27, 37–48. [Google Scholar] [CrossRef]
- Chang, L.; Geng, B.; Yu, F.; Zhao, J.; Jiang, H.; Du, J.; Tang, C. Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids 2008, 34, 573–585. [Google Scholar] [CrossRef]
- Wang, Y.; Shi, S.; Dong, S.; Wu, J.; Song, M.; Zhong, X.; Liu, Y. Sodium hydrosulfide attenuates hyperhomocysteinemia rat myocardial injury through cardiac mitochondrial protection. Mol. Cell. Biochem. 2015, 399, 189–200. [Google Scholar] [CrossRef]
- Givvimani, S.; Kundu, S.; Narayanan, N.; Armaghan, F.; Qipshidze, N.; Pushpakumar, S.; Vacek, T.P.; Tyagi, S.C. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Arch Physiol. Biochem. 2013, 119, 65–74. [Google Scholar] [CrossRef]
- Joseph, J.; Joseph, L.; Devi, S.; Kennedy, R.H. Effect of anti-oxidant treatment on hyperhomocysteinemia-induced myocardial fibrosis and diastolic dysfunction. J. Heart Lung Transplant. 2008, 27, 1237–1241. [Google Scholar] [CrossRef]
- Li, W.; Tang, R.; Ouyang, S.; Ma, F.; Liu, Z.; Wu, J. Folic acid prevents cardiac dysfunction and reduces myocardial fibrosis in a mouse model of high-fat diet-induced obesity. Nutr. Metab. 2017, 14, 68. [Google Scholar] [CrossRef]
- Tyagi, N.; Moshal, K.S.; Lominadze, D.; Ovechkin, A.V.; Tyagi, S.C. Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip goldblatt hypertension mouse model. Can. J. Physiol. Pharmacol. 2005, 83, 583–594. [Google Scholar] [CrossRef]
- Shi, Y.; Zhao, L.; Zhang, Y.; Qin, Q.; Cong, H.; Guo, Z. Homocysteine promotes cardiac fibrosis by regulating the Akt/FoxO3 pathway. Ann. Transl. Med. 2021, 9, 1732. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Q.; Song, W.; Huang, J.; Wang, D.; Xu, C. Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy. Curr. Res. Transl. Med. 2021, 69, 103270. [Google Scholar] [CrossRef] [PubMed]
- Carroll, J.F.; Tyagi, S.C. Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am. J. Hypertens. 2005, 18, 692–698. [Google Scholar] [CrossRef] [PubMed]
- Zulli, A.; Hare, D.L.; Buxton, B.F.; Black, M.J. The combination of high dietary methionine plus cholesterol induces myocardial fibrosis in rabbits. Atherosclerosis 2006, 185, 278–281. [Google Scholar] [CrossRef] [PubMed]
- Han, L.; Tang, Y.; Li, S.; Wu, Y.; Chen, X.; Wu, Q.; Hong, K.; Li, J. Protective mechanism of SIRT1 on hcy-induced atrial fibrosis mediated by TRPC3. J. Cell. Mol. Med. 2020, 24, 488–510. [Google Scholar] [CrossRef]
- Zhi, H.; Luptak, I.; Alreja, G.; Shi, J.; Guan, J.; Metes-Kosik, N.; Joseph, J. Effects of direct renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS ONE 2013, 8, e81612. [Google Scholar] [CrossRef]
- Zhang, J.-S.; Hou, Y.-L.; Lu, W.-W.; Ni, X.-Q.; Lin, F.; Yu, Y.-R.; Tang, C.-S.; Qi, Y.-F. Intermedin (1–53) protects against myocardial fibrosis by inhibiting endoplasmic reticulum stress and inflammation induced by homocysteine in apolipoprotein e-deficient mice. J. Atheroscler. Thromb. 2016, 23, 1294–1306. [Google Scholar] [CrossRef]
- Muthuramu, I.; Singh, N.; Amin, R.; Nefyodova, E.; Debasse, M.; Van Horenbeeck, I.; Jacobs, F.; De Geest, B. Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress. Klin. Wochenschr. 2015, 93, 609–618. [Google Scholar] [CrossRef]
- Wang, Z.-S.; Jin, H.; Wang, D.-M. Influence of hydrogen sulfide on zymogen activation of homocysteine-induced matrix metalloproteinase-2 in H9C2 cardiocytes. Asian Pac. J. Trop. Med. 2016, 9, 489–493. [Google Scholar] [CrossRef] [PubMed]
- Chaouad, B.; Moudilou, E.N.; Ghoul, A.; Zerrouk, F.; Moulahoum, A.; Othmani-Mecif, K.; Cherifi, M.E.H.; Exbrayat, J.-M.; Benazzoug, Y. Hyperhomocysteinemia and myocardial remodeling in the sand rat, psammomys obesus. Acta. Histochem. 2019, 121, 823–832. [Google Scholar] [CrossRef]
- Joseph, J.; Kennedy, R.H.; Devi, S.; Wang, J.; Joseph, L.; Hauer-Jensen, M. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am. J. Physiol. Circ. Physiol. 2005, 288, H2541–H2545. [Google Scholar] [CrossRef] [PubMed]
- Joseph, J.; Washington, A.; Joseph, L.; Kennedy, R.H. Hyperhomocysteinaemia-induced atrial remodelling in hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2004, 31, 331–337. [Google Scholar] [CrossRef] [PubMed]
- Cao, P.; Zhang, W.; Kong, X.; Gao, N.; Zhao, X.; Xu, R. Hyperhomocysteinemia-induced Nrf2/HO-1 pathway suppression aggravates cardiac remodeling of hypertensive rats. Biochem. Biophys. Res. Commun. 2021, 547, 125–130. [Google Scholar] [CrossRef]
- Li, C.; Zhang, R.; Zhan, Y.; Zheng, J. Resveratrol Inhibits Hepatic Stellate Cell Activation via the Hippo Pathway. Mediat. Inflamm. 2021, 2021, 3399357. [Google Scholar] [CrossRef]
- Chaturvedi, P.; Kalani, A.; Givvimani, S.; Kamat, P.K.; Familtseva, A.; Tyagi, S.C. Differential regulation of DNA methylation versus histone acetylation in cardiomyocytes during HHcy in vitro and in vivo: An epigenetic mechanism. Physiol. Genom. 2014, 46, 245–255. [Google Scholar] [CrossRef]
- Herrmann, M.; Taban-Shoma, O.; Hubner, U.; Pexa, A.; Kilter, H.; Umanskaya, N.; Straub, R.H.; Böhm, M.; Herrmann, W. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin. Chem. 2007, 53, 773–780. [Google Scholar] [CrossRef] [PubMed]
- Jeremic, J.; Turnic, T.N.; Zivkovic, V.; Jeremic, N.; Milosavljevic, I.; Srejovic, I.; Obrenovic, R.; Jancic, S.; Rakocevic, M.; Matic, S.; et al. Vitamin B complex mitigates cardiac dysfunction in high-methionine diet-induced hyperhomocysteinemia. Clin. Exp. Pharmacol. Physiol. 2018, 45, 683–693. [Google Scholar] [CrossRef]
- Kar, S.; Shahshahan, H.R.; Kambis, T.N.; Yadav, S.K.; Li, Z.; Lefer, D.J.; Mishra, P.K. Hydrogen sulfide ameliorates homocysteine-induced cardiac remodeling and dysfunction. Front. Physiol. 2019, 10, 598. [Google Scholar] [CrossRef]
- Raaf, L.; Noll, C.; Cherifi, M.E.H.; Samuel, J.-L.; Delcayre, C.; Delabar, J.-M.; Benazzoug, Y.; Janel, N. Myocardial fibrosis and TGFB expression in hyperhomocysteinemic rats. Mol. Cell. Biochem. 2011, 347, 63–70. [Google Scholar] [CrossRef]
- Mishra, P.K.; Tyagi, N.; Kundu, S.; Tyagi, S.C. Micro RNAs are involved in homocysteine-induced cardiac remodeling. Cell Biophys. 2009, 55, 153–162. [Google Scholar] [CrossRef] [Green Version]
- Rosenberger, D.; Gargoum, R.; Tyagi, N.; Metreveli, N.; Sen, U.; Maldonado, C.; Tyagi, S. Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 492–498. [Google Scholar] [CrossRef] [PubMed]
- Ables, G.P.; Ouattara, A.; Hampton, T.G.; Cooke, D.; Perodin, F.; Augie, I.; Orentreich, D.S. Dietary methionine restriction in mice elicits an adaptive cardiovascular response to hyperhomocysteinemia. Sci. Rep. 2015, 5, 8886. [Google Scholar] [CrossRef] [PubMed]
- Cainzos-Achirica, M.; Acquah, I.; Dardari, Z.; Mszar, R.; Greenland, P.; Blankstein, R.; Bittencourt, M.; Rajagopalan, S.; Al-Kindi, S.G.; Polak, J.F.; et al. Long-Term Prognostic Implications and Role of Further Testing in Adults Aged ≤55 Years With a Coronary Calcium Score of Zero (from the Multi-Ethnic Study of Atherosclerosis). Am. J. Cardiol. 2021, 161, 26–35. [Google Scholar] [CrossRef] [PubMed]
- Cai, B.; Gong, D.; Chen, N.; Li, J.; Wang, G.; Lu, Y.; Yang, B. The negative inotropic effects of homocysteine were prevented by matrine via the regulating intracellular calcium level. Int. J. Cardiol. 2011, 150, 113–115. [Google Scholar] [CrossRef]
- Shontz, R.D.; Xu, Z.; Patel, K.P.; Rozanski, G.J. Inhibition of K+ currents by homocysteine in rat ventricular myocytes. J. Cardiovasc. Electrophysiol. 2001, 12, 175–182. [Google Scholar] [CrossRef] [PubMed]
- Sun, W.T.; Hou, H.T.; Chen, H.X.; Xue, H.M.; Wang, J.; He, G.W.; Yang, Q. Calcium-activated potassium channel family in coronary artery bypass grafts. J. Thorac. Cardiovasc. Surg. 2021, 161, e399–e409. [Google Scholar] [CrossRef]
- Cai, B.; Shan, L.; Gong, D.; Pan, Z.; Ai, J.; Xu, C.; Lu, Y.; Yang, B. Homocysteine modulates sodium channel currents in human atrial myocytes. Toxicology 2009, 256, 201–206. [Google Scholar] [CrossRef]
- Lopatina, E.V.; Kipenko, A.; Penniyaynen, V.; Pasatetskaya, N.; Djuric, D.; Krylov, B. Organotypic tissue culture investigation of homocysteine thiolactone cardiotoxic effect. Acta Physiol. Hung. 2015, 102, 137–142. [Google Scholar] [CrossRef]
- Cai, B.-Z.; Gong, D.-M.; Liu, Y.; Pan, Z.-W.; Xu, C.-Q.; Bai, Y.-L.; Qiao, G.-F.; Lu, Y.-J.; Yang, B.-F. Homocysteine inhibits potassium channels in human atrial myocytes. Clin. Exp. Pharmacol. Physiol. 2007, 34, 851–855. [Google Scholar] [CrossRef]
- Pacher, P.; Ungvari, Z.; Kecskemeti, V. Electrophysiological effects of homocysteine in isolated rat right ventricular papillary muscles and left atria. Gen. Pharmacol. Vasc. Syst. 1999, 32, 439–443. [Google Scholar] [CrossRef]
- Soni, C.V.; Tyagi, S.C.; Todnem, N.D.; Givvimani, S.; Pushpakumar, S.B.; Villafane, J.; Maldonado, C. Hyperhomocysteinemia alters sinoatrial and atrioventricular nodal function: Role of magnesium in attenuating these effects. Cell Biophys. 2016, 74, 59–65. [Google Scholar] [CrossRef] [PubMed]
- Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiol. 2017, 13, 279–296. [Google Scholar] [CrossRef] [PubMed]
- Mishra, P.K.; Awe, O.; Metreveli, N.; Qipshidze, N.; Joshua, I.G.; Tyagi, S.C. Exercise mitigates homocysteine—β2-adrenergic receptor interactions to ameliorate contractile dysfunction in diabetes. Int. J. Physiol. Pathophysiol. Pharmacol. 2011, 3, 97–106. [Google Scholar] [PubMed]
- Mishra, P.K.; Givvimani, S.; Metreveli, N.; Tyagi, S.C. Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. Biochem. Biophys. Res. Commun. 2010, 401, 175–181. [Google Scholar] [CrossRef] [PubMed]
- Tasatargil, A.; Sadan, G.; Karasu, E.; Ozdem, S. Changes in atrium and thoracic aorta reactivity to adenosinergic and adrenergic agonists in experimental hyperhomocysteinemia. J. Cardiovasc. Pharmacol. 2006, 47, 673–679. [Google Scholar] [CrossRef]
- Moshal, K.S.; Kumar, M.; Tyagi, N.; Mishra, P.K.; Metreveli, N.; Rodriguez, W.E.; Tyagi, S.C. Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1. Am. J. Physiol. Circ. Physiol. 2009, 296, H887–H892. [Google Scholar] [CrossRef]
- Moshal, K.S.; Tipparaju, S.M.; Vacek, T.P.; Kumar, M.; Singh, M.; Frank, I.E.; Patibandla, P.K.; Tyagi, N.; Rai, J.; Metreveli, N.; et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am. J. Physiol. Circ. Physiol. 2008, 295, H890–H897. [Google Scholar] [CrossRef]
- Tyagi, N.; Vacek, J.C.; Givvimani, S.; Sen, U.; Tyagi, S.C. Cardiac specific deletion of N-methyl-d-aspartate receptor 1 ameliorates mtMMP-9 mediated autophagy/mitophagy in hyperhomocysteinemia. J. Recept. Signal Transduct. 2010, 30, 78–87. [Google Scholar] [CrossRef]
- Srejovic, I.; Zivkovic, V.; Nikolic, T.; Jeremic, N.; Stojic, I.; Jeremic, J.; Djuric, D.; Jakovljevic, V. Modulation of N-methyl-d-aspartate receptors in isolated rat heart. Can. J. Physiol. Pharmacol. 2017, 95, 1327–1334. [Google Scholar] [CrossRef]
- Busingye, D.; Pollack, A.; Chidwick, K. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study. PLoS ONE 2021, 16, e0252458. [Google Scholar] [CrossRef]
- Ji, C.; Yu, Y.; Zhang, M.; Yu, W.; Dong, S. Loxoprofen Sodium Alleviates Oxidative Stress and Apoptosis Induced by Angiotensin II in Human Umbilical Vein Endothelial Cells (HUVECs). Drug Des. Dev. Ther. 2020, 14, 5087–5096. [Google Scholar] [CrossRef]
- Xie, C.; Li, Q.; Li, L.; Peng, X.; Ling, Z.; Xiao, B.; Feng, J.; Chen, Z.; Chang, D.; Xie, L.; et al. Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19. J. Inflamm. Res. 2021, 14, 1207–1216. [Google Scholar] [CrossRef]
- Samman Tahhan, A.; Sandesara, P.B.; Hayek, S.S.; Alkhoder, A.; Chivukula, K.; Hammadah, M.; Mohamed-Kelli, H.; O’Neal, W.T.; Topel, M.; Ghasemzadeh, N.; et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017, 14, 1849–1855. [Google Scholar] [CrossRef]
- Korantzopoulos, P.; Letsas, K.; Fragakis, N.; Tse, G.; Liu, T. Oxidative stress and atrial fibrillation: An update. Free Radic. Res. 2018, 52, 1199–1209. [Google Scholar] [CrossRef]
- Sen, U.; Basu, P.; Abe, O.A.; Givvimani, S.; Tyagi, N.; Metreveli, N.; Shah, K.S.; Passmore, J.C.; Tyagi, S.C. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am. J. Physiol. Physiol. 2009, 297, F410–F419. [Google Scholar] [CrossRef]
- Ripps, H.; Shen, W. Review: Taurine: A “very essential” amino acid. Mol. Vis. 2012, 18, 2673–2686. [Google Scholar]
- Wu, D.; Gu, Y.; Zhu, D. Cardioprotective effects of hydrogen sulfide in attenuating myocardial ischemia-reperfusion injury (Review). Mol. Med. Rep. 2021, 24, 875. [Google Scholar] [CrossRef]
- Fu, M.; Chen, H.; Cai, Z.; Yang, Y.; Feng, Z.; Zeng, M.; Chen, L.; Qin, Y.; Cai, B.; Zhu, P.; et al. Forkhead box family transcription factors as versatile regulators for cellular reprogramming to pluripotency. Cell Regen. 2021, 10, 17. [Google Scholar] [CrossRef]
- Ronnebaum, S.M.; Patterson, C. The foxo family in cardiac function and dysfunction. Annu. Rev. Physiol. 2010, 72, 81–94. [Google Scholar] [CrossRef]
- Allessie, M.; Ausma, J.; Schotten, U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 2002, 54, 230–246. [Google Scholar] [CrossRef]
- Mládková, J.; Hladílková, J.; Diamond, C.E.; Tryon, K.; Yamada, K.; Garrow, T.A.; Jungwirth, P.; Koutmos, M.; Jiráček, J. Specific potassium ion interactions facilitate homocysteine binding to betaine-homocysteine S-methyltransferase. Proteins Struct. Funct. Bioinform. 2014, 82, 2552–2564. [Google Scholar] [CrossRef]
- Schnabel, R.; Lackner, K.J.; Rupprecht, H.J.; Espinola-Klein, C.; Torzewski, M.; Lubos, E.; Bickel, C.; Cambien, F.; Tiret, L.; Münzel, T.; et al. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: Results from the atherogene study. J. Am. Coll. Cardiol. 2005, 45, 1631–1637. [Google Scholar] [CrossRef] [PubMed]
- Ay, H.; Arsava, E.M.; Tokgozoglu, S.L.; Ozer, N.; Sarıbas, O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 2003, 34, 909–912. [Google Scholar] [CrossRef]
- Loffredo, L.; Violi, F.; Fimognari, F.L.; Cangemi, R.; Sbrighi, P.S.; Sampietro, F.; Mazzola, G.; Di Lecce, V.N.; D’Angelo, A. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica 2005, 90, 1205–1211. [Google Scholar] [PubMed]
- Sundström, J.; Sullivan, L.; Selhub, J.; Benjamin, E.J.; D’Agostino, R.B.; Jacques, P.F.; Rosenberg, I.H.; Levy, D.; Wilson, P.W.; Vasan, R.S. Relations of plasma homocysteine to left ventricular structure and function: The framingham heart study. Eur. Heart J. 2004, 25, 523–530. [Google Scholar] [CrossRef] [PubMed]
- Alter, P.; Rupp, H.; Rominger, M.B.; Figiel, J.; Renz, H.; Klose, K.J.; Maisch, B. Association of hyperhomocysteinemia with left ventricular dilatation and mass in human heart. Clin. Chem. Lab. Med. (CCLM) 2010, 48, 555–560. [Google Scholar] [CrossRef]
- Li, Z.; Guo, X.; Sun, G.; Zheng, L.; Sun, Y.; Liu, Y.; Abraham, M.R. Plasma homocysteine levels associated with a corrected QT interval. BMC Cardiovasc. Disord. 2017, 17, 182. [Google Scholar] [CrossRef]
- Leng, Y.L.Y.; Zhou, Y.; Ke, H.; Jelinek, H.; McCabe, J.; Assareh, H.; McLachlan, C.S. Electrocardiogram derived QRS duration >120 ms is associated with elevated plasma homocysteine levels in a rural australian cross-sectional population. Medicine 2015, 94, e1080. [Google Scholar] [CrossRef]
- Gueant-Rodriguez, R.-M.; Juillière, Y.; Nippert, M.; Abdelmouttaleb, I.; Herbeth, B.; Aliot, E.; Danchin, N.; Guéant, J.-L. Left ventricular systolic dysfunction is an independent predictor of homocysteine in angiographically documented patients with or without coronary artery lesions. J. Thromb. Haemost. 2007, 5, 1209–1216. [Google Scholar] [CrossRef]
- Guéant Rodriguez, R.M.; Spada, R.; Pooya, S.; Jeannesson, E.; Moreno Garcia, M.A.; Anello, G.; Bosco, P.; Elia, M.; Romano, A.; Alberto, J.M.; et al. Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int. J. Cardiol. 2013, 167, 768–775. [Google Scholar] [CrossRef]
- Görmüş, U.; Özmen, D.; Özmen, B.; Parıldar, Z.; Özdogan, O.; Mutaf, I.; Bayindir, O. Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res. Clin. Pract. 2010, 87, 51–56. [Google Scholar] [CrossRef] [PubMed]
- Cho, S.E.; Hong, K.S.; Shin, G.J.; Chung, W.S. The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea. Clin. Chem. Lab. Med. (CCLM) 2006, 44, 1070–1075. [Google Scholar] [CrossRef] [PubMed]
- Ye, P.; Cao, R.; Bai, Y.; Xu, R. Homocysteine is associated with plasma high-sensitivity cardiac troponin T levels in a community-dwelling population. Clin. Interv. Aging 2014, 9, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Alam, N.; Khan, H.I.L.R.; Chowdhury, A.W.; Haque, M.S.; Ali, M.S.; Sabah, K.M.N.; Amin, M.G. Elevated serum homocysteine level has a positive correlation with serum cardiac troponin I in patients with acute myocardial infarction. Bangladesh Med. Res. Counc. Bull. 2012, 38, 9–13. [Google Scholar] [CrossRef]
- Wang, S.; Wei, Y.; Hidru, T.H.; Li, D.; Wang, N.; Yang, Y.; Wang, Y.; Yang, X.; Xia, Y. Combined effect of homocysteine and uric acid to identify patients with high risk for subclinical atrial fibrillation. J. Am. Heart Assoc. 2022, 11, e021997. [Google Scholar] [CrossRef] [PubMed]
- Wocial, B.; Berent, H.; Kostrubiec, M.; Kuczyńska, K.; Kuch-Wocial, A.; Niewegłowska, N. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 2002, 11, 201–205. [Google Scholar] [CrossRef]
- Poduri, A.; Kaur, J.; Thakur, J.S.; Kumari, S.; Jain, S.; Khullar, M. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension. J. Hum. Hypertens. 2008, 22, 289–294. [Google Scholar] [CrossRef]
- Atar, I.; Korkmaz, M.E.; Demircan, S.; Atar, A.; Bozbaş, H.; Aydinalp, A.; Özin, B.; Yildirir, A.; Müderrisoğlu, H. Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis 2005, 181, 399–402. [Google Scholar] [CrossRef]
- Chua, W.; Purmah, Y.; Cardoso, V.R.; Gkoutos, G.; Tull, S.P.; Neculau, G.; Thomas, M.; Kotecha, D.; Lip, G.Y.H.; Kirchhof, P.; et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur. Heart J. 2019, 40, 1268–1276. [Google Scholar] [CrossRef]
- Fabritz, L. The power of P in the elderly: Small biphasic wave, big impact. Heart Rhythm 2016, 13, 652–653. [Google Scholar] [CrossRef]
- Attia, Z.I.; Noseworthy, P.A.; Lopez-Jimenez, F.; Asirvatham, S.J.; Deshmukh, A.J.; Gersh, B.J.; Carter, R.E.; Yao, X.; Rabinstein, A.A.; Erickson, B.J.; et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction. Lancet 2019, 394, 861–867. [Google Scholar] [CrossRef]
- Siontis, K.C.; Yao, X.; Pirruccello, J.P.; Philippakis, A.A.; Noseworthy, P.A. How will machine learning inform the clinical care of atrial fibrillation? Circ. Res. 2020, 127, 155–169. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, T.; Sakamoto, K.; Yamano, T.; Kikkawa, M.; Zen, K.; Hikosaka, T.; Kubota, T.; Azuma, A.; Nishimura, T. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2002, 39, 1657–1663. [Google Scholar] [CrossRef]
- Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.J.; Horsley, T.; Weeks, L.; et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann. Intern. Med. 2018, 169, 467–473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Reference | Number of Participants | Results |
---|---|---|
Kubota et al., 2019 [11] | 7133 patients from Atherosclerosis Risk in Communities (ARIC) Study and Multi-Ethnic Study of Atherosclerosis (MESA) |
|
Marcucci et al., 2004 [12] | 310 NVAF patients on oral anticoagulant treatment (168 patients with previous ischemic events and 142 without) and 310 controls |
|
Nasso et al., 2013 [13] | 104 patients after minimally invasive epicardial ablation |
|
Naji et al., 2010 [14] | 83 patients with persistent AF after successful electrical cardioversion |
|
Shi et al., 2016 [15] | 132 patients with both hypertension and AF (78 with paroxysmal AF and 84 with persistent AF) and 136 hypertensive patients |
|
Shimano et al., 2008 [16] | 62 paroxysmal or persistent AF patients undergoing RFCA |
|
Schnabel et al., 2010 [17] | 3120 Framingham cohort participants |
|
Cingozbay et al., 2002 [18] | 38 patients with non-valvular AF divided into two groups: group A (patients with AF and stroke) and group B (AF without stroke) plus a reference group of 15 patients |
|
Yao et al., 2017 [19] | 257 consecutive patients with persistent AF who underwent catheter ablation |
|
Yao et al., 2017 [20] | Review |
|
Giusti et al., 2007 [21] | 456 NVAF patients and 912 matched controls |
|
Svenningsson et al., 2020 [22] | 3535 patients with no history of AF |
|
META-ANALYSES | ||
Rong et al., 2020 [23] | 11 studies with 3974 patients |
|
Dong et al., 2021 [24] | 5 studies with 13,556 patients |
|
Reference | Model | Potential Mechanism |
---|---|---|
Bayrak et al., 2021 [25] | Copenhagen rats | Oxidative Stress |
Borkowska et al., 2021 [26] | HUVEC and SH-SY5Y cells | Oxidative Stress |
Cheng et al., 2021 [27] | C57BL/6 mouse aortae ex vivo | Oxidative Stress |
Guo et al., 2021 [28] | 24 studies assessed | Oxidative Stress |
Sharma et al., 2021 [29] | several proteins and enzymes. | Oxidative Stress |
Boyacioglu et al., 2014 [30] | Wistar rats | Oxidative Stress |
Aminzadeh et al., 2018 [31] | H9C2 myocardial cells | Oxidative Stress |
Derouiche et al., 2014 [32] | Male Wistar rats (Pasteur Institute-Algiers) | Oxidative Stress |
Aissa et al., 2017 [33] | Mice | Oxidative Stress |
Dittoe et al., 2011 [34] | Rat neonatal cardiomyoblasts (H9c2 cells) | Oxidative Stress |
Kolling et al., 2011 [35] | Hearts of young rats | Oxidative Stress |
Devi et al., 2006 [36] | Spontaneously hypertensive rats | Oxidative Stress |
Han et al., 2020 [37] | C57BL/6J mice | Oxidative Stress |
Mendes et al., 2010 [38] | Male Wistar rats | Oxidative Stress |
Singh et al., 2008 [39] | Rats | Oxidative Stress |
Stojanovic et al., 2016 [40] | Isolated rat hearts | Oxidative Stress |
Timkova et al., 2016 [41] | Rats | Oxidative Stress |
Yalçinkaya-Demirsözm et al., 2009 [42] | Rabbits | Oxidative Stress |
Chang et al., 2004 [43] | Rat myocardial mitochondria | Oxidative Stress and Taurine |
Chang et al., 2004 [44] | Rat isolated myocardial mitochondria | Oxidative Stress and Taurine |
Chang et al., 2008 [45] | Rats | Oxidative Stress and H2S |
Wang et al., 2015 [46] | Rats | Oxidative Stress and H2S |
Givvimani et al., 2011 [47] | Mouse cardiac endothelial cells | Oxidative Stress and Fibrosis |
Joseph et al., 2008 [48] | Rat model | Oxidative Stress and Fibrosis |
Li et al., 2017 [49] | Six-week-old C57BL6/J mice | Oxidative Stress and Fibrosis |
Tyagi et al., 2005 [50] | Mice | Oxidative Stress and Fibrosis |
Shi et al., 2021 [51] | 2–3 days old Wistar rats | Fibrosis |
Zhao et al., 2021 [52] | C57BL/6 mice with a high L-methionine (L-MET) diet for 12 weeks | Fibrosis |
Carroll et al., 2005 [53] | Rabbit model | Fibrosis |
Zulli et al., 2006 [54] | Rabbits | Fibrosis |
Han et al., 2020 [55] | Left atrial appendage from patients with either sinus rhythm (SR) or AF | Fibrosis |
Zhi et al., 2013 [56] | Mice | Fibrosis |
Zhang et al., 2016 [57] | Apolipoprotein E-deficient (ApoE −/−) mice and neonatal rat cardiac fibroblasts (CFs) | Fibrosis |
Muthuramu et al., 2015 [58] | Female C57BL/6 low-density lipoprotein receptor (Ldlr (−/−)) cystathionine-β-synthase (Cbs (+/−)) mice | Fibrosis |
Wang et al., 2016 [59] | Cardiocytes H9C2 | Fibrosis |
Chaouad et al., 2019 [60] | Sand rat Psammomys obesus | Fibrosis and Remodeling |
Joseph et al., 2005 [61] | Mast cell-deficient rat model | Fibrosis, Remodeling and Diastolic Dysfunction |
Joseph et al., 2004 [62] | Hypertensive rats | Fibrosis, Remodeling and Diastolic Dysfunction |
Cao et al., 2021 [63] | Hypertensive rats | Fibrosis and Diastolic Dysfunction |
Li et al., 2021 [64] | Mouse CFs | Fibrosis and Diastolic Dysfunction |
Cao et al., 2021 [63] | Wistar Kyoto (WKY) and spontaneous hypertension rats (SHR) | Remodeling |
Chaturvedi et al., 2014 [65] | HL-1 cardiomyocytes and mouse models (CBS+/−) | Remodeling |
Herrmann et al., 2007 [66] | Rats | Remodeling |
Jeremic et al., 2018 [67] | Adult male Wistar albino rats | Remodeling |
Kar et al., 2019 [68] | Male CBS(+/−) and sibling CBS(+/+) (WT) mice | Remodeling |
Raaf et al., 2011 [69] | Rats | Remodeling |
Mishra et al., 2009 [70] | HL-1 cardiomyocytes | Remodeling |
Rosenberger et al., 2011 [71] | male C57/BL6J mice | Remodeling |
Li et al., 2021 [64] | Male C57BL/6J mice | Endothelial dysfunction |
Ables et al., 2015 [72] | Μice | ECG |
Cainzos-Achirica et al., 2021 [73] | 1407 participants (61% women) without diabetes or severe hypercholesterolemia | Calcium |
Cheng et al., 2021 [27] | Human umbilical vein endothelial cells (HUVECs)-derived EA.hy926 immortalized cells | Calcium |
Cai et al., 2011 [74] | Wistar rat hearts | Calcium |
Shontz et al., 2001 [75] | Whole-cell voltage-clamp recordings were made in ventricular myocytes isolated from normal rat hearts | Ca2+-independent, transient outward Potassium (K+) current (I(to)) |
Sun et al., 2021 [76] | Residual internal mammary artery (IMA) segments obtained from patients undergoing CABG | Potassium Calcium (K(Ca)) |
Cai et al., 2007 [77] | Human atrial cells | Potassium |
Lopatina et al., 2015 [78] | Chicken embryo cardiac tissue explants | Potassium, Sodium |
Cai et al., 2009 [79] | Human atrial monocytes. | Sodium |
Pacher et al., 1999 [80] | Isolated rat hearts | Sodium |
Soni et al., 2016 [81] | Wild-type mice (WT) | Magnesium |
Han et al., 2020 [82] | Mouse atrial myocytes (MACs) obtained from C57B6 mice. | Electrical Remodeling |
Mishra et al., 2011 [83] | cardiomyocytes obtained from C57BL/6J (WT) and db/db mice. | β2-AR |
Mishra et al., 2010 [84] | 12 week male diabetic Ins2+/− Akita and C57BL/6J mice | β2-AR |
Tasatargil et al., 2006 [85] | Adult male Wistar rats | β2-AR |
Moshal et al., 2009 [86] | Cardiomyocyte-specific knockout of NMDA-R1 | NMDA-R1 |
Moshal et al., 2008 [87] | C57BL/6J mice | NMDA-R1 |
Tyagi et al., 2010 [88] | Cardiac-specific knockout (KO) of NMDA-R1 | NMDA-R1 |
Srejovic et al., 2017 [89] | Hearts of Wistar albino rats | NMDA-R1 |
Busingye et al., 2021 [90] | 600 human population | Inflammation |
Ji et al., 2020 [91] | human umbilical vein endothelial cells (HUVECs) | Inflammation |
Xie et al., 2021 [92] | mice | Inflammation |
Reference | Number of Participants | Results |
---|---|---|
Schnabel et al., 2005 [102] | 643 patients with coronary artery disease |
|
Ay et al., 2003 [103] | 42 consecutive patients with ischemic stroke caused by nonvalvular AF |
|
Loffredo et al., 2005 [104] | 163 consecutive patients with permanent (n = 118) or paroxysmal (n = 45) AF of non-valvular origin hospitalized for cardiac reasons |
|
Sundström et al., 2004 [105] | 2697 Framingham Heart Study participants free of heart failure and previous myocardial infarction | Plasma Hcy was positively related to LV mass, wall thickness, and relative wall thickness in women, but not in men. |
Alter et al., 2010 [106] | 66 individuals with suspected cardiomyopathy |
|
Li et al., 2017 [107] | 7002 healthy individuals |
|
Leng et al., 2015 [108] | 178 healthy individuals |
|
Guéant-Rodriguez et al., 2007 [109] | 515 patients with coronary artery disease and 194 patients without evidence of coronary artery lesion |
|
Guéant-Rodriguez et al., 2013 [110] | 1020 subjects including patients undergoing coronarography and ambulatory elderly subjects |
|
Görmüş et al., 2010 [111] | 31 patients with type 2 diabetes mellitus |
|
Cho et al., 2006 [112] | 227 patients with cardiovascular disease |
|
Ye et al., 2014 [113] | 1497 healthy individuals |
|
Alam et al., 2012 [114] | 194 consecutive patients with acute myocardial infarction |
|
Wang et al., 2022 [115] | 1224 consecutive patients with cardiac implantable electronic devices |
|
Wocial et al., 2002 [116] | 37 patients with mild essential hypertension (EH) and 37 healthy volunteers | Hcy was significantly higher in patients with EH (8.7 +/− 2.4 vs. 6.6 +/− 1.3 μmol/L; p < 0.01). |
Poduri et al., 2008 [117] | 273 patients with essential hypertension (EH) and 103 normotensive controls |
|
Atar et al., 2005 [118] | 120 patients with newly diagnosed hypertension |
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Charalampidis, P.; Teperikidis, E.; Boulmpou, A.; Papadopoulos, C.E.; Potoupni, V.; Tsioni, K.; Rakitzi, P.; Karamitsos, T.; Vassilikos, V. Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature. Diagnostics 2022, 12, 2192. https://doi.org/10.3390/diagnostics12092192
Charalampidis P, Teperikidis E, Boulmpou A, Papadopoulos CE, Potoupni V, Tsioni K, Rakitzi P, Karamitsos T, Vassilikos V. Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature. Diagnostics. 2022; 12(9):2192. https://doi.org/10.3390/diagnostics12092192
Chicago/Turabian StyleCharalampidis, Panagiotis, Eleftherios Teperikidis, Aristi Boulmpou, Christodoulos E. Papadopoulos, Victoria Potoupni, Konstantina Tsioni, Pantelitsa Rakitzi, Theodoros Karamitsos, and Vassilios Vassilikos. 2022. "Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature" Diagnostics 12, no. 9: 2192. https://doi.org/10.3390/diagnostics12092192